罗欣药业: 北京市金杜律师事务所上海分所关于罗欣药业集团股份有限公司2024年年度股东大会之法律意见书

Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of shareholders for Luoxin Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association [1][2][3]. Group 1: Meeting Procedures - The meeting was convened on May 12, 2025, at the designated location, and the actual time, place, and manner of the meeting were consistent with the prior announcements [4][6]. - The legal opinion asserts that the procedures for convening and holding the meeting complied with legal and regulatory requirements [3][4]. Group 2: Attendance and Qualifications - A total of 170 shareholders attended the meeting, representing 242,426,486 shares, which is 22.8368% of the total voting shares [5][6]. - The qualifications of the attendees, including institutional and individual shareholders, were verified and found to be in compliance with legal requirements [5][6]. Group 3: Voting Procedures and Results - The voting process was conducted through a combination of on-site and online voting, with the results being verified by the legal representatives present [6][8]. - The voting results showed that the majority of proposals were approved, with significant support from shareholders, including 99.8776% approval for one of the key resolutions [8][12].